{"name": "Repligen",
 "permalink": "repligen",
 "crunchbase_url": "http://www.crunchbase.com/company/repligen",
 "homepage_url": "http://www.repligen.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "investors@repligen.com",
 "phone_number": "781.250.0111",
 "description": "",
 "created_at": "Fri Dec 17 02:59:31 UTC 2010",
 "updated_at": "Tue Nov 01 02:30:18 UTC 2011",
 "overview": "\u003Cp\u003ERepligen Corporation (Repligen) is a biopharmaceutical company focused on the development and commercialization of therapies that harness biological pathways and deliver value to patients and clinicians in neurology, gastroenterology and orphan diseases. As of March 31, 2010, the Company was conducting a number of drug development programs for diseases, such as pancreatitis, bipolar disorder, Friedreich\u00e2\u20ac\u2122s ataxia and spinal muscular atrophy. It also has a bioprocessing business that focuses on the development and commercialization of products that are used for the production of biopharmaceuticals. Repligen sells a line of commercial bioprocessing products based on Protein A, as well as single or limited campaign use pre-packed chromatography columns, which are used in the production of monoclonal antibodies and other biopharmaceutical manufacturing applications. In March 2010, the Company announced that it acquired the assets of BioFlash Partners, LLC, (BioFlash). \u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       45],
      "assets/images/resized/0011/4400/114400v1-max-150x150.png"],
     [[230,
       70],
      "assets/images/resized/0011/4400/114400v1-max-250x250.png"],
     [[230,
       70],
      "assets/images/resized/0011/4400/114400v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "President and CEO",
    "person":
     {"first_name": "Walter",
      "last_name": "C. Herlihy",
      "permalink": "walter-c-herlihy",
      "image": null}},
   {"is_past": false,
    "title": "CFO",
    "person":
     {"first_name": "William",
      "last_name": "J. Kelly",
      "permalink": "william-j-kelly",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$1.4M",
 "funding_rounds":
  [{"round_code": "grant",
    "source_url": "http://www.masshightech.com/stories/2010/12/13/daily32-Repligen-awarded-14M-for-spinal-muscular-atrophy-research.html",
    "source_description": "Repligen awarded $1.4M for spinal muscular atrophy research",
    "raised_amount": 1400000.0,
    "raised_currency_code": "USD",
    "funded_year": 2010,
    "funded_month": 12,
    "funded_day": 15,
    "investments":
     []}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "41 Seyon Street",
    "address2": "Building #1, Suite 100",
    "zip_code": "02453",
    "city": "Waltham",
    "state_code": "MA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "reported positive results from a Phase 3 study of RG1068",
    "stoned_year": 2011,
    "stoned_month": 3,
    "stoned_day": 14,
    "source_url": "http://www.masshightech.com/stories/2011/03/14/daily14-Repligen-gets-positive-results-on-improved-pancreatic-MRI.html",
    "source_text": null,
    "source_description": "Repligen gets positive results on improved pancreatic MRI",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Repligen",
      "permalink": "repligen"}},
   {"description": "concluded a pre-New Drug Application (NDA) meeting with U.S. Food and Drug Administration officials",
    "stoned_year": 2011,
    "stoned_month": 6,
    "stoned_day": 1,
    "source_url": "http://www.masshightech.com/stories/2011/05/30/daily20-Repligen-targets-NDA-for-pancreatic-imaging-technology.html",
    "source_text": null,
    "source_description": "Repligen targets NDA for pancreatic imaging technology",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Repligen",
      "permalink": "repligen"}},
   {"description": "Repligen to buy Novozymes Biopharma unit for $22.7M",
    "stoned_year": 2011,
    "stoned_month": 10,
    "stoned_day": 27,
    "source_url": "http://www.masshightech.com/stories/2011/10/24/daily42-Repligen-to-buy-Novozymes-Biopharma-unit-for-227M.html",
    "source_text": "",
    "source_description": "Repligen to buy Novozymes Biopharma unit for $22.7M",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Repligen",
      "permalink": "repligen"}}],
 "ipo":
  {"valuation_amount": null,
   "valuation_currency_code": "USD",
   "pub_year": null,
   "pub_month": null,
   "pub_day": null,
   "stock_symbol": "NASDAQ:RGEN"},
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}